ArticleThe Journal of experimental medicine2019
Concomitant
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 83 citations in OpenAlex.
- A Comprehensive Literature Review and Case Report of Severe Lymphoproliferative Disease Secondary toJournal of clinical medicine · 2026Article
- Avoidance of related donors in CAEBV with germline immune variants: long-termoutcome of matched unrelated donor HSCT - a case report.Annals of hematology · 2026Article
- Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine.Discover oncology · 2026Review
- Investigating concomitant RAG-2 and LRBA mutations in SCID and autoimmunity.Clinical and experimental immunology · 2026Article
- Expression profiling of Epstein-Barr virus-derived microRNA in systemic chronic active EBV disease.International journal of hematology · 2025Article
- Somatic reversion in CD137 deficiency correlating with Epstein-Barr virus control and clinical improvement.NPJ genomic medicine · 2025Article
- Homozygous Loss of Function PIK3CD Mutation in Multiple Siblings Leading To B Cell Dysregulation and Autoimmunity.Journal of clinical immunology · 2025Article
- The impact of genetic immune disorders on infections including COVID-19, inflammatory bowel disease and cancer.Nature immunology · 2025Review
- Article
- Clinical and functional characterization of a novelFrontiers in immunology · 2025Article
- A differential diagnosis method for systemic CAEBV and the prospect of EBV-related immune cell markers via flow cytometry.Annals of medicine · 2024Review
- Article
- 4-1BB immunotherapy: advances and hurdles.Experimental & molecular medicine · 2024Review
- Technical challenges of intracellular flow cytometry-based assays as a functional complement to diagnosis of signaling defects of inborn errors of immunity: PI3K pathway as a case of study.Frontiers in immunology · 2024Article
- Study on gene expression in the liver at various developmental stages of human embryos.Frontiers in cell and developmental biology · 2024Article
- Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.Frontiers in immunology · 2024Review
- Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.Journal of clinical immunology · 2023Review
- Rescuing the cytolytic function of APDS1 patient T cells via TALEN-mediated PIK3CD gene correction.Molecular therapy. Methods & clinical development · 2023Article
- Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2023Article
- Novel target and treatment agents for natural killer/T-cell lymphoma.Journal of hematology & oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Rémy Rodriguez *Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Benjamin Fournier *Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.ORCID 0000-0002-4189-996X
Debora Jorge Cordeiro *Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Sarah Winter *Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Kazushi IzawaLaboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.ORCID 0000-0003-1080-0936
Emmanuel MartinLaboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.ORCID 0000-0003-4211-7373
David BoutboulLaboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Christelle LenoirLaboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Sylvie FraitagDepartment of Pathology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Sven KrackerUniversity Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
Tania H WattsDepartment of Immunology, University of Toronto, Toronto, Canada.ORCID 0000-0001-7897-4890
Capucine PicardLaboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France.
Julie BruneauUniversity Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
Isabelle CallebautSorbonne Université, Muséum National d'Histoire Naturelle, Centre National de la Recherche Scientifique Unité Mixte de Recherche 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Paris, France.
Alain FischerUniversity Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.ORCID 0000-0003-4025-5983
Bénédicte NevenUniversity Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
Sylvain LatourLaboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Institut National de la Santé et la Recherche Médicale, Unité Mixte de Recherche 1163, Paris, France sylvain.latour@inserm.fr.ORCID 0000-0001-8238-4391
Université Paris Cité · FRHôpital Necker-Enfants Malades · FRCentre National de la Recherche Scientifique · FRUniversity of Toronto · CA
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection of T cells by Epstein-Barr virus (EBV) causes chronic active EBV infection (CAEBV) characterized by T cell lymphoproliferative disorders (T-LPD) of unclear etiology. Here, we identified two homozygous biallelic loss-of-function mutations in
Indexed as
Class I Phosphatidylinositol 3-KinasesDisease SusceptibilityEpstein-Barr Virus InfectionsGerm-Line MutationHerpesvirus 4, HumanHistocytochemistryHomozygoteHumansImmunophenotypingLoss of Function MutationLymphocyte ActivationLymphoproliferative DisordersModels, MolecularPedigreePhospholipase C gammaProtein ConformationClass I Phosphatidylinositol 3-KinasesPhospholipase C gammaPIK3CD protein, humanPLCG1 protein, humanProto-Oncogene Proteins c-aktRibosomal Protein S6 KinasesTNFRSF9 protein, humanTumor Necrosis Factor Receptor Superfamily, Member 9
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.